Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$9.33 USD
+0.29 (3.21%)
Updated May 14, 2024 04:00 PM ET
After-Market: $9.32 -0.01 (-0.11%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
FOLD 9.33 +0.29(3.21%)
Will FOLD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FOLD
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Other News for FOLD
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim gets more bullish on Amicus, upgrades shares
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...